Table 2.
Adverse events for direct and indirect comparisons
| Adverse event | Odds ratio (95% CI)a | ||
|---|---|---|---|
| Direct comparisonsb | Indirect comparisonsc | ||
| TBZ‐placebo | DEU‐placebo | TBZ‐DEU | |
| Serious adverse events, as defined by study authors | 5.44 (0.28, 104.49) | 1.00 (0.06, 16.50) | 5.44 (0.09, 322.08) |
| Somnolence | 13.32 (1.67, 106.07)d | 2.69 (0.49, 14.64) | 4.95 (0.34, 72.37) |
| Diarrhea | 0.72 (0.15, 3.46) | 9.87 (0.52, 188.88) | 0.07 (0.03, 2.06) |
| Insomnia | 21.84 (1.25, 380.62)d | 1.54 (0.24, 9.66) | 14.18 (0.47, 426.77) |
| Fatigue | 1.86 (0.54, 6.37) | 1.54 (0.24, 9.66) | 1.21 (0.31, 11.14) |
| Falls | 1.30 (0.36, 4.64) | 0.48 (0.08, 2.74) | 2.71 (0.31, 23.98) |
| Depression | 11.15 (0.62, 200.33) | 0.65 (0.10, 4.10) | 17.15 (0.55, 531.90) |
CI, confidence interval; TBZ, tetrabenazine; DEU, deutetrabenazine.
a
All values are odds ratios with 95% CIs in parentheses, with 1 indicating absence of difference. CIs not spanning 1 indicate a statistically significantly altered odds.
b
For direct comparisons, values greater than 1 indicate an increased odds in the active treatment arm.
c
For indirect comparisons, values greater than 1 indicate an increased odds for TBZ.
d
Significantly favors placebo.